Synthetic approaches to the 2013 new drugs

被引：66
作者：
Ding, Hong X. [1 ]
Leverett, Carolyn A. [4 ]
Kyne, Robert E., Jr. [4 ]
Liu, Kevin K. -C. [2 ]
Fink, Sarah J. [3 ]
Flick, Andrew C. [4 ]
O'Donnell, Christopher J. [4 ]
机构：
[1] Pharmacodia Beijing Co Ltd, Beijing 100085, Peoples R China
[2] Lilly China Res & Dev Ctr, Shanghai 201203, Peoples R China
[3] BioDuro Co Ltd, Shanghai 200131, Peoples R China
[4] Pfizer Worldwide Res & Dev, Groton Labs, Groton, CT 06340 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2015年 / 23卷 / 09期
关键词：
Synthesis; New drug molecules; New chemical entities; Medicine; Therapeutic agents; ADENOSINE RECEPTOR ANTAGONISTS; PALLADIUM-CATALYZED SYNTHESIS; PARKINSONS-DISEASE; DOUBLE-BLIND; ENANTIOSELECTIVE SYNTHESIS; ASYMMETRIC-SYNTHESIS; SELECTIVE INHIBITOR; DISCOVERY; 1ST; MACITENTAN;
D O I：
10.1016/j.bmc.2015.02.056
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1895 / 1922
页数：28
相关论文
共 223 条
[101]  
Krueger T., 2011, US Patent, Patent No. [20110124859A1, 20110124859]
[102]   TRASTUZUMAB EMTANSINE Tumor-Activated Prodrug (TAP) Immunoconjugate Oncolytic [J].
Kumler, I. ;
Mortensen, C. Ehlers ;
Nielsen, D. L. .
DRUGS OF THE FUTURE, 2011, 36 (11) :825-832
[103]   Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer [J].
Lambert, John M. ;
Chari, Ravi V. J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (16) :6949-6964
[104]  
Lee C.S., 2006, [WO Patent, WO Patent], Patent No. [2006/104356 A1, 2006104356]
[105]   Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial [J].
Lennox, Jeffrey L. ;
Dejesus, Edwin ;
Lazzarin, Adriano ;
Pollard, Richard B. ;
Ramalho Madruga, Jose Valdez ;
Berger, Daniel S. ;
Zhao, Jing ;
Xu, Xio ;
Williams-Diaz, Angela ;
Rodgers, Anthony J. ;
Barnard, Richard J. O. ;
Miller, Michael D. ;
DiNubile, Mark J. ;
Nguyen, Bach-Yen ;
Leavitt, Randi ;
Sklar, Peter .
LANCET, 2009, 374 (9692) :796-806
[106]   Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005) [J].
LeWitt, Peter A. ;
Guttman, M. ;
Tetrud, James W. ;
Tuite, Paul J. ;
Mori, Akihisa ;
Chaikin, Philip ;
Sussman, Nell M. .
ANNALS OF NEUROLOGY, 2008, 63 (03) :295-302
[107]   Synthetic approaches to the 2004 new drugs [J].
Li, J ;
Liu, KKC ;
Sakya, S .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (12) :1133-1144
[108]   Synthetic approaches to the 2002 new drugs [J].
Li, J ;
Liu, KKC .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (02) :207-233
[109]  
Li J., 2013, WO Patent, Patent No. [2013086935A1, 2013086935]
[110]  
[李亮 LI Liang], 2011, [中国药物化学杂志, Chinese Journal of Medicinal Chemistry], V21, P120
6789101112131415